oral semaglutide cardiovascular outcomes soul trial results 2024 2025 A emulation in Nature Medicine shows that treatment with and tirzepatide showed similar levels of benefit on in people at elevated cardiovascular risk with obesity and diabetes. Link soul trial oral semaglutide cardiovascular

Patented cross-cut design ensures a close fit to the contours of the face, including the nose and chin

3-product wellness bundle with Trim Biome, Night Shred & Inno Shred GLP-1. Prebiotics, probiotics & postbiotics

Currently: BPC-157 is not FDA-approved There are no standardized treatment guidelines Long-term human safety data is lacking Large randomized clinical trials have not been completed Optimal dosing protocols have not been established Because most published research comes from animal studies, scientists cannot yet determine whether the same effects occur in humans

Product Care & Storage Store at -20C (freezer) for long-term stability

Hany Demian, MD, a board-certified physician in pain management and aesthetic medicine and the CEO and founder of Praesentia Health and BioSpine Institute in Fort Myers, Florida

Preclinical studies have suggested that GLP-1 receptors are expressed in thyroid tissue, and animal models have indicated possible anti-inflammatory effects that could theoretically influence autoimmune processes